Skip to main content

Table 3 Infections reported in BRASS and confirmed through chart review

From: Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement

Infection type

Reported in BRASSa

Confirmed by chart review

In total cohort

Confirmed by chart review

In trimmed cohortb

 

N (column %)

Upper respiratory infection

274 (36%)

188 (25%)

84 (28%)

Sinus infection

207 (27%)

100 (13%)

48 (16%)

Genitourinary tract

163 (21%)

90 (12%)

34 (11%)

Bronchitis/pneumonia

154 (20%)

96 (12%)

46 (16%)

Skin, soft tissue

123 (16%)

173 (23%)

64 (21%)

Otitis media

33 (4%)

12 (2%)

4 (1%)

Bone or joint

27 (4%)

23 (3%)

4 (1%)

Blood stream

9 (1%)

10 (1%)

4 (1%)

Gastrointestinal

---

26 (3%)

4 (1%)

Oral/dental

---

15 (2%)

4 (1%)

Ophthamalogic

---

9 (1%)

2 (1%)

Lyme disease

---

7 (1%)

4 (1%)

Unknown source

264 (34%)

19(3%)

3 (1%)

Total

1254

768

305

  1. aThe infections reported in BRASS, by patients or rheumatology providers, were used in the sensitivity analysis reported in Fig. 2a. Columns may not add up to 100% because of rounding
  2. bThis column only includes infections occurring after the start of a new DMARD; these infections were used in the main analysis